Journal article
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
AM Jubb, H Turley, HC Moeller, G Steers, C Han, JL Li, R Leek, EY Tan, B Singh, NJ Mortensen, I Noguera-Troise, F Pezzella, KC Gatter, G Thurston, SB Fox, AL Harris
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2009
Abstract
Background:Delta-like ligand 4 (Dll4) is a Notch ligand that is upregulated by hypoxia and vascular endothelial growth factor-A (VEGF-A) and is reported to have a role in tumor angiogenesis. Evidence from xenograft studies suggests that inhibiting Dll4-Notch signalling may overcome resistance to anti-VEGF therapy. The aim of this study was to characterise the expression of Dll4 in colon cancer and to assess whether it is associated with markers of hypoxia and prognosis.Method:In all, 177 colon cancers were represented in tissue microarrays. Immunohistochemistry was performed using validated antibodies against Dll4, VEGF, hypoxia-inducible factor (HIF)-1α, HIF-2α, prolyl hydroxylase (PHD)1, P..
View full abstractGrants
Awarded by Cancer Research UK
Funding Acknowledgements
This study received financial support from Cancer Research UK, the Experimental Cancer Medicine Centre Network, the European Union Metoxia Framework and the NIHR Biomedical Research Centre, Oxford.